Philipp le Coutre

机构：Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin · ORCID：0000-0003-4532-1097

发表论文 293 篇 · 总被引 12047 次 · h-index 50

代表论文

• Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results (2025 · Leukemia · 被引 13)
• Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial (2025 · Blood · 被引 12)
• Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results (2025 · Leukemia · 被引 12)
• Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL (2025 · Blood Advances · 被引 11)
• Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study (2024 · Blood · 被引 7)
• The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients (2024 · Blood · 被引 6)